.

FIP ANNUAL REPORT 2010-2011

Sharing knowledge around the world
Annual Report 2010-2011

1

2

FIP ANNUAL REPORT 2010-2011

FIP CEO and General Secretary Mr A.J.M. Hoek
On behalf of the International Pharmaceutical Federation,
FIP, our 124 Member Organisations and in turn the two million
pharmacists and pharmaceutical scientists we represent
globally, I am pleased to present to you our 2010-2011 Annual
Report.
The focus of this year’s Annual Report is the impact and
influence FIP has around the world as THE global Federation
of pharmacists and pharmaceutical scientists. This year has
exemplified that FIP is matched by none in its ability to gather
the world’s visionaries into one far-reaching network and in
turn disseminate top calibre pharmacy and pharmaceutical
sciences knowledge to all corners of the globe.
Throughout 2010-2011, FIP has demonstrated its unique ability
to grow in scope and action while at the same time fine-tuning
its influence in specific regions of the world, to a variety of
audiences and in a needs-based way. This Annual Report
presents the best of how FIP has shared knowledge around
the world over the past year.

3

4

FIP ANNUAL REPORT 2010-2011

FIP PRESIDENT.
MICHEL BUCHMANN, PhD.
Worldwide, activity is intensifying towards
the implementation of our joint Vision 2020
for global Pharmacy. By sharing our expe­
riences and knowledge, our organisation
and profession is growing from strong to
stronger. In this first year in my role as FIP
­
President, I have had the opportunity to
meet FIP members from every region of the
globe. Through discussing with members
and FIP officers at various meetings and
events, I am confident that we are working
together to ensure the best quality, safety
and health for our communities. From meetings in Brazil to China to Seattle to The
Hague, what has impressed me the most is
the passion and deep responsibility I see in
our Members’ that is greatly complemented
by their efforts to develop the profession
and science of pharmacy.

Every pharmacist and pharmaceutical scientist makes
important contributions to society. The richness and reward of
seeing these contributions affecting our communities has kept
us working hard for the past 100 years and will continue to
drive us forward in the future.
FIP is working diligently with key partners towards the
implementation of the 2020 Strategic Plan at the global level.
We know what we want to achieve and are now taking the
necessary steps to engage deeply with decision-makers. FIP
Member Organisations are also working with key national
partners to develop and implement their sisions and roles
within their healthcare systems. By working in synergy and
sharing successes and failures we will be better able to take
risks, innovate and build a strong future for pharmacy practice
and science.
Internally, FIP is building important links between the Board of
Pharmaceutical Sciences and Board of Pharmacy Practice.
Pharmacists are the unquestionable experts on medications
and their safe and effective use. Pharmaceutical scientists are
the unquestionable experts in medicines innovation, quality
and safety. As scientists develop new medicines, they gain by
working closely with practicing pharmacists to better understand the needs of society; by pharmacy practitioners working
with scientists they can better understand the therapeutic
gains possible. Pharmacists must add the professional services
necessary so that these medicines become treatments that
actually save lives.
We have widely disseminated FIP’s strategic plan and activities
internally and now we are focusing our attention on disseminating these messages externally, with global decision-makers
and actors such as Joseph Deiss, the current President of the
United Nations General Assembly. The FIP Executive were
invited and received by the President Deiss in New York last
June. NCDs will form the topic of a high-level summit at the UN
General Assembly in September 2011 and the meeting provided
the opportunity to inform President Deiss of the value
pharmacists bring to the table when involved in the prevention
and treatment of non-communicable diseases.

5

6

FIP ANNUAL REPORT 2010-2011

It is a landmark year in FIP’s continued collaboration with the
World Health Organization (WHO). This year FIP and WHO
approved and published joint guidelines on good pharmacy
practice (GPP). These guidelines are a vital tool in strengthening
our case that “Pharmacists should always have input into
decisions about the use of medicines.” The time is ripe to use
these guidelines to strengthen pharmacy practice around the
world. We must promote excellence in practice for the benefit
of those served. As stated in the guidelines, “our profession will
be judged on how we translate our commitment into practice
in all settings”. This is a strong affirmation from the World
Health Organization that pharmacists are an essential part of
any comprehensive health system; and that pharmacists play
an important role in improving access to health care and
closing the gap between the potential benefit and the actual
value realized from medicines.
Further to FIP partnerships in the global health arena, we are
pleased to announce the FIP and Lilly Millennium Development
Goals (MDG) – Tuberculosis (TB) Partnership, which is being
fulfilled via the FIP SEARPharm Forum. This is a unique
­public-private collaboration with the support of Lilly MDR TB
in partnership with Government, Chemists Association and the
Indian Pharmaceutical Association (IPA) in India that will serve
to train pharmacists in the detection, referral, medicines
management and counseling of TB in 4 to 5 major cities in India.
FIP is very proud to be part of this unique initiative and
encourage all to become more aware of and involved in the
project.
Together, we are sharing and achieving tangible, positive
impact on health and the responsible use of medicines around
the world. The annual report provides you with greater detail
of FIP’s progress over the past year in our worldwide initiatives.
Enjoy searching and clicking through this report, in what is a
great example of the use of new information technology to
disseminate our activities widely.
Michel Buchmann, PhD
FIP President
2010-2014

7

8

FIP ANNUAL REPORT 2010-2011

70TH FIP WORLD CONGRESS.
OF PHARMACY AND.
PHARMACEUTICAL SCIENCES.
Every year, FIP organises the World Congress
of Pharmacy and Pharmaceutical Sciences,
where thousands of pharmacists meet, learn,
share knowledge and exchange views.
In 2010 the FIP Congress took place in Lisbon, Portugal, with
almost 3000 participants convening on this historical city. The
key event of the FIP Congress Lisbon was the election of a new
FIP President, Dr Michel Buchman (Switzerland). Dr Buchmann
will serve a four year term (to 2014) following the Presidency of
Dr Kamal K. Midha, who will carry on as FIP Immediate Past
President.
Dr Buchmann is assuming the role of FIP president after
extensive experience within FIP Boards, community pharmacy
practice and Swiss politics. In his remarks following the release
of the Election Results Dr Buchmann reiterated his commitment to advancing FIP’s Strategic Plan to advance pharmacy
practice, the pharmaceutical sciences and pharmacy education
on a global level.
The programme, posters and exhibition FIP offered the
thousands of visiting participants were the best the world had
to offer with respect to the latest developments in pharmacy
practice and pharmaceutical sciences. The Congress hosted 266
speakers from 50 different countries, truly demonstrating that
FIP and its Congress is the hub of international information
exchange for pharmacy practice and science.

The FIP Congress – impact on Portugal
The Portuguese Host Committee, headed by President João
Silveira, must be commended for their efforts in creating an
exceptional Congress atmosphere for participants, staff and
visitors alike. The Congress itself came to Portugal at a key
juncture, with Mr Silveira stating in the Congress Opening
Ceremony: “In this context of crisis and consequent changes in
financial, economic, social and geopolitical paradigms, which
directly affect health systems and the fields of pharmacy and
medicine, it is our duty as pharmacists to help find solutions
that suit the needs and expectations of our fellow citizens,
based on our professional knowledge and scientific ethics.”
Portuguese Minister of Health Ana Jorge, also present at the
Opening Ceremony, was quick to echo his comments, saying
that “it is the pharmacist who, ultimately, ensures access to
appropriate treatment, both from a clinical and an economic
point of view”.
Mr Silveira went on to reflect that the simple fact of hosting the
most representative congress of the profession worldwide is
already a sign of the entrepreneurship and the commitment of
Portuguese pharmacists. The congress was not only extremely
valuable for the individual participants but also to project the
image and the role of the pharmacists in society in Portugal and
internationally. The credibility of the profession – he concluded
– was reinforced at all levels by this congress.
The Host Committee also did an excellent job of generating
media coverage for the congress, with nine press releases
produced and made available to Portuguese media, resulting
in 180 pieces published throughout the country. Mr Silveira was
also interviewed for the national television news programme
SIC Notícias.

9

10

FIP ANNUAL REPORT 2010-2011

11

International Media Attention – FIP reaches new audiences
For the first time in 2010 FIP upped its efforts to reach broad
media attention by releasing two press releases based on
submitted abstracts and one on a joint FIP-Pfizer survey on
pharmacists:
• Health advice from pharmacists saves hundreds of millions
of euros, study shows (Dr Erkki Kostiainen, Finland)
• Study shows that widespread parental misuse of medicines
puts children at risk (Dr Rebekah Moles, Australia)
• International Survey shows new generation of pharmacists
significantly improving patients’ health, but concerns about
counterfeit medicines and ongoing training are growing ­
(FIP and Pfizer)
FIP achieved international attention with the press releases,
most significantly being profiled on the BBC Health webpage.
This media outreach was the first of many endeavours that FIP
will undertake to increase our visibility within global media,
especially as we move forward to the FIP Centennial. This first
attempt shows that the work FIP showcases in our Congress,
and within the Federation, is growing in significance and
attention on a global level.

Awards at the FIP Congress
FIP feels it is of utmost importance to support and recognise
individuals who, through their vision and commitment to their
profession, are making outstanding contributions to the fields
of pharmacy practice and pharmaceutical sciences. As such,
each year FIP honours those who have demonstrated commendable work and dedication in areas which parallel the
overall FIP mission of advancing pharmacy practice, science
and education for the betterment of global health. This in turn
emphasises the importance the Federation places on not only
sharing knowledge with others, but also on fostering the
development of those who bring knowledge to FIP.
Award winners are announced and welcomed each year at the
Opening Ceremony of the FIP Congress. At the 2010 Congress in
Lisbon the following individuals were honoured for their
ongoing contributions to pharmacy practice and the pharmaceutical sciences:

12

FIP ANNUAL REPORT 2010-2011

FIP Awards 2010:
FIP Distinguished Science Award
Prof. Hideyoshi Harashima (Japan)
FIP Lifetime Achievement In Pharmaceutical Science Award
Prof. Hans E. Junginger (Germany)
FIP Fellows
Prof. Daan Crommelin (The Netherlands)
Prof. James T. Doluisio (USA)
Prof. Mitsuru Hashida (Japan)
Prof. Bert Leufkens (The Netherlands)
Prof. Phil Schneider (USA)
Mrs Linda Stone (UK)
André Bedat Award
Prof. Charlie Benrimoj (Australia)
FIP Honorary Membership
Dr John Gans (USA)

FIP Congress Speakers – the world shares its knowledge
with FIP
As the largest international meeting for pharmacists and
pharmaceutical scientists, the annual FIP Congress prides itself
on the wide range of knowledge and geographical locations
represented each year by invited speakers. The 2010 Congress in
Lisbon was no exception, with 266 speakers from 50 different
countries, exemplifying the truly global context in which knowledge and insight is presented to visiting participants.

13

14

FIP ANNUAL REPORT 2010-2011

15

16

FIP ANNUAL REPORT 2010-2011

FIP SECTIONS,.
SPECIAL INTEREST GROUPS AND.
REGIONAL PHARMCEUTICAL FORUMS.
AT THE FIP CONGRESS AND BEYOND

FIP encompasses within its network nine
Practice Sections and ten Scientific Special
Interest Groups (SIGs) which are actively
pursuing FIP’s objectives of advancing
pharmacy practice and science (respectively)
on a global level. In addition, FIP works with
the World Health Organization (WHO) to
maintain FIP Pharmaceutical Forums
­representing the WHO regions of the world.

More information on each individual Section, SIG and Forum,
including their full 2010-2011 Annual Reports can be accessed
by clicking the links below:
The Sections of Pharmaceutical Practice
- Academic Pharmacy
- Clinical Biology
- Community Pharmacy
- Hospital Pharmacy
- Industrial Pharmacy
- Laboratories and Medicines Control Section
- Military and Emergency Pharmacy
- Pharmacy Information
- Social and Administrative Pharmacy

The Scientific Special Interest Groups
- Bioavailability and Bioequivalence
- BCS and Biowaiver
- Dissolution/Drug Release
- Environment and Pharmaceuticals
- Individualized Medicine
- Medicinal Chemistry
- Natural Products
- Nuclear Pharmacy
- Pharmaceutical Biotechnology
- Pharmacoepidemiology and Pharmacoeconomics

FIP Regional Pharmaceutical Forums
- EuroPharm Forum
- Pharmaceutical Forum of the Americas
- South East Asian Region Pharmaceutical Forum
- Western Pacific Pharmaceutical Forum
- Eastern-Mediterranean Forum
- African Forum

17

During the FIP Congress, the Sections, SIGs and often the
Forums hold special sessions and workshops catering to
individual members of FIP who are members of that Section or
SIG, or visiting Congress participants who are not FIP Members
but who are interested in the topics presented.
In addition, many of these groups organise workshops and
activities outside the FIP Congress in different areas of the
world. Reports of all activities, Congress and otherwise, can be
found within each group’s own annual report, available via the
links above. Below are some highlights of the work these FIP
bodies are doing to share knowledge on a global level:

Highlights from FIP SIGs:
• FIP SIG Dissolution/Drug Release: “Hands-on-Dissolution”
workshop was organized together with FEFAS congress May
2010 in Porto Alegre (Brazil). A bioequivalence, bioanalysis,
dissolution and biosimilar workshop was held in June 2010
in Budapest, Hungary
• FIP SIG Natural Products was represented at the FEFAS
congress by Dr Carmen Tomayo who presented on Medicinal
Plants and Phytomedicines. The Conference later released
an official Conference letter on Medicinal Plants and
­Phytomedicines
• The SIG on BCS and Biowaiver has published several Bio­
waiver monographs of Active Pharmaceutical Ingredients
(APIs) for medicines on the WHO List of Essential Drugs in the
Journal of Pharmaceutical Science. This activity is continued.
By now, SIG BCS and Biowaiver have published over 25
monographs.
• FIP SIG on Nuclear Pharmacy was represented throughout
Latin American throughout 2010-2011 to bring their expertise
on the topic to conferences in the region

18

FIP ANNUAL REPORT 2010-2011

Highlights from FIP Sections:
• Representative from the FIP Community Pharmacy Section
participated in a quality indicator workshop in Thailand
(November 2010) to promote FIP’s Good Pharmacy Practice
philosophy
• In May 2010, the FIP Pharmacy Information Section was
represented at an advisory board meeting for the World
Economic Forum Global Health Data Charter project.
This is an ambitious project designed to advance global
health through improved data collection and management.
The Charter was launched in early 2011 and has been
endorsed by FIP.
• The FIP Military and Emergency Pharmacy (MEPS) Section
was represented at the Pharmacy Australia Congress in
Melbourne the US Joint Forces Symposium.
• FIP Section on Clinical Biology has been active within the
International Federation for Clinical Chemistry.
• FIP Industrial Pharmacy Section helped organise and
participated in the following meetings and events :
- Tablet Manufacturing Technologies, Cairo, Egypt,
January 2010.
- FIP/WHO Training Workshop on Pharmaceutical
­Development with focus on Paediatric Formulations
in Beijing, China June, 2010
- 15th International Pharmaceutical Technology Sympo­
sium Antalya, Turkey, September 2010.
- Session at the Dutch Medicines Days Amsterdam,
The Netherlands
- South Africa’s SAAPI – “Risk Management”, GMPs for the
QC Lab”, “Essentials of Validation” , South Africa,
­November 2010.

19

20

FIP ANNUAL REPORT 2010-2011

PHARMACEUTICAL SCIENCES.
WORLD CONGRESS (PSWC).
NEW ORLEANS, USA.
In 2010 FIP’s Pharmaceutical Sciences World
Congress (PSWC) was jointly held with the
American Association of Pharmaceutical
Sciences (AAPS) Annual Meeting and
­Exposition. This was the first time these two
influential bodies within the pharmaceutical
sciences combined efforts for an international conference. The meeting brought
together thousands of scientists from
around the world with the goal of
­“Improving Global Health Through Advances
in Pharmaceutical Sciences,” the scientific
theme of this year‘s event.

A tremendous amount of planning went into making this the
premier event of the year for pharmaceutical scientists. Nearly
50 supporting or co-sponsoring organizations worldwide
promoted the event, increasing both attendance and media
coverage.
The PSWC/AAPS Meeting showcased late-breaking research,
validated scientific methodology, and revealed the latest
technology, services and supplies for research needs. Speakers
included scientists from the U.S. Food and Drug Administration,
National Institute of Health, leading pharmaceutical companies
and academia.
Expert speakers addressed topics such as:
- global health
- medicinal chemistry
- excipients
- global regulatory changes
- model based drug development
- drug product safety
- stability
- unstable metabolites
- nanotechnology

21

Media coverage of PSWC
Media coverage surrounding the 2010 PSWC meeting was a
resounding success, generating more than twice the amount of
coverage as 2009’s AAPS Annual Meeting and Exposition. When
coverage from the audio news release (ANR) is factored in,
media coverage more than tripled. In total, 729 articles/radio
segments appeared in print, broadcast and online outlets
nationally and internationally, resulting in 458.6 million media
impressions both within the US and internationally.
In addition to FIP holding a significant presence in the PSWC/
AAPS Exhibition, representatives from the FIP Board of
Pharmaceutical Science and FIP Scientific Special Interest
Groups also contributed to specific sessions and workshops
throughout the event:
- FIP Board of Pharmaceutical Sciences (BPS) results from the
survey on the Impact of Pharmaceutical Sciences in the
Healthcare Arena presented at PSWC ‘Hot Topics’
- FIP SIG on BCS and Biowaiver: workshop on “Harmonization
– of regulatory approaches for evaluating therapeutical
equivalence and interchange­ability of multisource and
complex drug products”
- FIP SIG on Dissolution/Drug Release: symposium on
“In-vitro Release of Novel Dosage Forms”
- FIP SIG on Natural Products: symposium on “Natural
Products: Interface between science and Practice”
- FIP SIG on Environment and Pharmaceuticals: mini-symposium on “Pharmaceutical Waste and Environmental Pollution
- FIP Industrial Pharmacy Section: symposia on Continuous
Manufacturing: Benefits and Challenges; ICH Guidelines Q8,
Q9, Q10, Q11: How do they all fit together?

22

FIP ANNUAL REPORT 2010-2011

23

24

FIP ANNUAL REPORT 2010-2011

FIP, PHARMACY EDUCATION AND.
THE GLOBAL HEALTH WORKFORCE.
THE FIP ACADEMIC INSTITUTIONAL
­MEMBERSHIP (AIM)
In March of 2010, FIP launched a brand new
membership – the FIP Academic Institutional
Membership, or FIP AIM.
Recognising a lack of involvement and Membership from
academic institutes and their leaders, the FIP AIM was esta­
blished to allow Faculties and Schools of Pharmacy to become
inter-connected on a global platform of discussion, leadership
and shared challenges and successes. The FIP AIM focuses on
the parallel evolution of Faculties and Schools of Pharmacy
alongside the ongoing changes in pharmacy practice, science,
research and their respective funding. All Faculties and Schools
of Pharmacy from around the world are welcome to apply for
a FIP AIM. These Academic Institutes are represented by their
Deans, Vice Deans and other Decision Makers within the
Membership activities such as online discussion platforms
and the annual International Dean’s Forum at the FIP Congress.
The first year of the FIP AIM was and continues to be a growing
success, with almost 60 Faculties of Pharmacy applying for
Membership. The world-wide interest shared amongst Deans
for a Deans-level platform for discussion and networking was
further exemplified at the first AIM Deans Forum, held at the
2010 FIP Congress in Lisbon, Portugal. Here, over 40 Deans of
Faculties of Pharmacy met for the two-day event that delved
into universally relevant topics such as strategic planning,
partnering for resources – financial and otherwise – and quality
assurance of curricula, staff and students. Enthusiastic
discussions went well past the scheduled sessions, a founda­
tion on which to move forward with the second AIM Deans
Forum being held at the 2011 FIP Congress in Hyderabad, India.

Further to in-person meetings and discussions, the FIP AIM
has developed an extensive website and online forum for
inter­action for all AIM Members and their representatives.
Here, Deans may continue the discussions that were sparked
at the Deans Forum all year, with faculty representatives
invited to connect within their own online platform.
As 2011 moves forward, so does the FIP AIM. It is the goal that
this new membership serves a unique demographic of Deans of
Faculties of Pharmacy and serves to support the ongoing goal
of advancing pharmacy education through the betterment of
academic institutes and their leaders.

FIP PHARMACY EDUCATION TASKFORCE
As part of a tri-partite agreement, WHO, UNESCO and FIP
endorsed the establishment of the Global Pharmacy Education
Taskforce. The Taskforce was official launched at the 1st Global
Health Workforce Alliance meeting of the WHO in Kampala
2008. This Taskforce has successfully implemented its’ 20082010 Action Plan; providing evidence-based support to facilitate
needs-based pharmacy education development.
Establishing a needs-based curriculum requires a participatory
process that engages key stakeholders.
As part of the recent pharmacy curriculum review at the
National University of Rwanda and curriculum development
for a new pharmacy school at the University of Namibia, the
needs-based education tools and frameworks developed by FIP
were implemented and utilised to support the review process.
In addition multiple leaders from FIP’s education initiatives
supported and acted as content experts in the review and
development processes.

25

FIP EDUCATION INITIATIVES
Through FIP’s Vision 2020 – Vision, Mission and Strategic Plan,
FIP is dedicated to advancing pharmacy education worldwide.
This goal exemplified by the long standing activities of the
­Academic Pharmacy Section, that have been further expanded
­
and developed through more recent initiatives including
the Academic Institutional Membership and the Pharmacy
­Education Taskforce.
FIPEd, FIP Education Initiatives, has been established as a
cohesive structure for the integration of all pharmacy
­education activities within FIP. FIPEd, and its newly appointed
Bureau level Steering Committee, will work to facilitate
previous efforts while fostering efficient evolution of future
initiatives.
FIPEd Initiatives aim to stimulate transformational change in
pharmaceutical education and engender the development of
science and practice, towards meeting present and future
societal and workforce needs around the world. These will be
achieved through:
- providing a global platform for exchange, mentoring and
learning for leaders and academics, focussing on the
development of leadership skills and academic management
and pedagogic skills;
- building, advocating for, and disseminating evidence-based
guidance, consensus-based standards, tools and resources
for educational development.
With the support and engagement of pharmacy education
institutions, FIP members, and global health and education
stakeholders, FIPEd will continue to build on achievements and
successes towards educating pharmacists and pharmaceutical
scientists that are relevant to the needs of society.

26

FIP ANNUAL REPORT 2010-2011

FIP at the 2nd Human Resources for Health Forum
Bangkok, Thailand 24-29th January 2011
In late January 2011, over 1000 participants took part in the
2nd Human Resources for Health Forum in Bangkok, Thailand.
FIP, represented by Project Manager Diane Gal, was on hand
to lend its growing knowledge on human resources for health,
strengthening the global pharmacy workforce and share its
activities within the FIP Pharmacy Education Taskforce. Fellow
participants included various high level representatives from
governments/ministries of health, non-governmental organi­
sations and civil society, health professions, AID organisations/
charities, global health organisations, The World Bank, WHO.

Summary of the Forum
The Forum was jointly organised by the Thai Prince Mahidol
Award Conference (PMAC), the Global Health Workforce Alliance
(GHWA), the World Health Organization (WHO) and the Japan
International Cooperation Agency (JICA). The theme of the
Forum was ‘Reviewing progress, renewing commitments to
health workers towards MDGs and beyond’.
The Forum aimed to accelerate the global movement on HRH
towards achieving the Millennium Development Goals and
universal access to health by:
1. Reporting on the commitments and progress made since the
Kampala Declaration and the Agenda for Global Action from
stakeholders, partners and countries. (read the progress
report on the Kampala Declaration and Agenda for Global
Action here.)
2. Having speakers and participants share country, regional
and sectoral experiences.
3. Building linkages between health system components and
promoting the capacities for networks and alliances.

FIP Activities - Raising awareness
FIP took several opportunities to raise awareness about
pharmacy education and the pharmacy workforce at the
Forum. These included:
- FIP organised a three hour session for Forum delegates and
external invited participants to celebrate and disseminate
information about the actions undertaken since the launch
of the Pharmacy Education Taskforce Action Plan at the 1st
Forum in 2008. At this session the new Pharmacy Support
Workforce Domain was officially launched.
- Pharmacy Education Case Story Poster and Plaque: The
Pharmacy Education Taskforce partnered with the Indian
Pharmaceutical Association to submit a case story entitled
“Quality assurance in pharmacy education: a cornerstone for
strengthening the pharmacy workforce in India” – one of the
36 chosen to be presented at the Forum. An English and
French poster of the story was made prominently available
at the Forum exhibition. The case story is included on the
GHWA website.
- Presentation at WHO Mapping of Health professional schools
meeting: Diane Gal presented the progress of the WHO-FIP
Pharmacy Schools Survey at the invitation only meeting
organised by Rebecca Bailey (WHO HRH). This meeting
brought together several institutions working towards
collecting data on health professional education to share
experiences and discuss the best way forward in maintaining
up-to-date data repositories that can inform education
investment and policy at the global level.

Main Outcomes of the Forum
Bangkok Outcome Statement- was adopted by the participants
at the Forum to reiterate the principles of the Kampala
Declaration and the Code as instruments for alignment and
accountability at global, regional, national and local levels, and
to call upon all stakeholders to accelerate implementation in a
comprehensive manner. Available online here.
FIP was pleased to have the opportunity to participate in the
Forum and both learn from and share with other participants
and organisations our work in improving human resources for
health.

27

28

FIP ANNUAL REPORT 2010-2011

REGIONAL.
COUNTERFEIT.
WORKSHOPS.
In 2000 FIP joined forces with the Interna­
tional Council of Nurses (ICN), World Medical
Association (WMA) and World Dental
­Federation (FDI), to found the World Health
­Professions Alliance (WHPA), established to
facilitate working together in support of
governments, policy makers and WHO in
order to better deliver cost-effective,
quality healthcare worldwide. Since then,
the WHPA has also welcomed the World
Confederation of Physical Therapists to the
Alliance, even further solidifying its con­
certed, multi-disciplinary actions towards
better health care.
In October and November 2010, the WHPA hosted two Regional
Workshops on Counterfeit Medicines, one in Costa Rica and one
in Nigeria. These workshops set out to raise awareness of the
problem of counterfeit medicines in specific areas as well as
arm the health professionals in those areas with the knowledge, skills and motivation necessary to fight this growing
threat to health.

Costa Rica
THE REGIONAL WORKSHOP IN COSTA RICA WAS A JOINT INITATIVE
BY THE HEALTH PROFESSIONS FROM CENTRAL AMERICA,
THE CARIBBEAN, COLOMBIA AND MEXICO
The first ever multi-professional workshop on counterfeit
medical products was held on 19 October, in Costa Rica’s capital
city of San José. Twenty-three national health professional
organisations who are members of the World Health
­Profes­sions Alliance (WHPA) met to discuss counterfeit medical
products, which all agreed are a public health problem and a
threat to patient safety with grave consequences in terms of
increased disease burden, mortality and costs for healthcare
systems.
Under the banner of the “Be Aware, Take Action” campaign
against counterfeit medical products, this was the first of a
series of WHPA workshops, aiming to tackle the serious
challenge of counterfeit medical products worldwide.
­Co-hosted with WHPA by the Pharmaceutical Society of Costa
Rica and the Pharmaceutical Forum of the Americas, the
workshop brought together participants from Colombia,
Costa Rica, the Dominican Republic, El Salvador, Guatemala,
­Honduras, Mexico, Nicaragua and Panama.
The workshop targeted joint strategies amongst the five WHPA
health professions to identify, report and purge counterfeit
medical products from the supply chain and to empower
patients to make the best decisions when it comes to acquiring,
carefully checking and using medical products.
Presenters included the Pan-American Health Organization,
the US Food and Drug Administration Office for Latin America
and the FIP Pharmaceutical Forum of the Americas. These
provided a clear picture of the severity and complexity of the
problem, as well as the efforts being made by these organisa­
tions to fight it and the legal framework available in each
country to define, combat and penalise the production and
distribution of counterfeit medical products.
29

There was consensus on the need to raise awareness about this
issue amongst healthcare professionals and the public in
general, through massive campaigns and training initiatives.
Likewise, participants unanimously agreed on the need for
strong and clear laws and institutions that prevent, pursue and
punish such crimes – laws that are written in collaboration with
healthcare professionals’ organisations and are based on their
technical input.

IMPACT and OUTCOME
Workshop participants agreed upon and signed the WHPA San
José Call to Action on Counterfeit Medical Products, addressed
to patients, healthcare professionals and their organisations
and health authorities and urging these stakeholders to
Be Aware and Take Action, as the WHPA campaign proposes.
The Call to Action, 19th October 2010, San José, Costa Rica
We, health professionals’ organisations from Central America
and the Spanish-Speaking Caribbean countries, as well as
Colombia and Mexico, have gathered in this first-ever, multi-­
disciplinary health professionals event addressing falsified and
counterfeit medical products, to recognize that such medical
products present a serious public health problem worldwide,
and to issue this Call to Action to patients, the general public,
health care professionals, and government officials.
We recognize that increased vigilance by health care professionals and patients can help make safer use of medical
products.
We are concerned that falsification and counterfeiting of
medical products, including the entire range of activities from
manufacturing to knowingly providing them to patients, is a
vile and serious criminal offense that puts human lives at risk
and undermines the credibility of health systems.
Likewise, we are concerned about the infiltration of such
products in the legitimate distribution chain, leading to the
unknowingly prescription, dispensing and administration of
such medicines to patients by healthcare professionals.
Accordingly, we issue this Call to Action to initiate concerted
action in our countries:

30

FIP ANNUAL REPORT 2010-2011

Patients and the general public:
We call on patients and the general public in our countries to:
• Only buy medicines from legal outlets, such as registered
pharmacies and appropriately trained personnel such as
registered pharmacists
• Never buy medicines from illegal or uncontrolled Internet
sites that hide their physical location and are not supervised
by properly trained health professionals.
• Report a suspected falsified or counterfeit medical product
to their attending health professional.
Health care professionals:
We call on health care professionals in our countries to:
• Work together across various disciplines to raise awareness
of and action against falsified and counterfeit medical
products amongst patients, the general public, their
colleagues and health authorities;
• Consider and report falsified and counterfeit medical
products as a reason when patients do not respond or have
an unexpected response to treatment;
• Always procure medical products from a legitimate distributor or wholesaler.
National organisations of healthcare professionals
We call on national organisations of health professionals to:
• Work together with the other organisations of healthcare
professionals in each country in order to optimise resources,
maximise the effectiveness of our efforts and pass on to the
public an image of cohesiveness of healthcare professions
around the challenge of counterfeit medical products.
• Work closely with the Pan American Network for Drug
Regulatory Harmonization (PANDRH) / Working Group for
Prevention and Combat Drug Counterfeiting, of the Pan
American Health Organization (PAHO).
• Encourage their members to take an active role in iden­
tifying, reporting and eliminating falsified or counterfeit
medical products from the distribution chain.
Government health officials:
We call on government health officials in our countries to:
• Adopt the WHO definition of falsified and counterfeit medical
products so that access to legitimate, safe, effective and
affordable generic medicines will not be hindered by
inappropriate intellectual property rights enforcement
• Conduct regular public campaigns educating patients and
the public about how they can protect themselves from the
dangers of falsified and counterfeit medical products
• Establish national reporting systems that enable health
professionals to report and to get feedback about adverse
events, drug-related problems, medication errors, misuse or
drug abuse, defects in product quality or detection of
falsified and counterfeit medical products.

The Participants of this WHPA workshop agree unanimously on
the SAN JOSÉ “CALL TO ACTION” and commit to plan and act in
cooperation in support of it.

Nigeria
REGIONAL WORKSHOP ON COUNTERFEIT MEDICAL PRODUCTS
Abuja, Nigeria 22-23 November 2010
The regional workshop aimed to bring together representatives
of national health professions organisations and relevant
authorities to:
- Share information and examples of initiatives and best
practices on the counterfeit medical products situation
throughout the region;
- Hold a discussion among health professions and relevant
authorities about how to spur action to reduce the
infiltra­tion of counterfeit medical products in the region;
- Discuss action plans for health professionals in each country
participating in the workshop so that the momentum
to combat counterfeits continues throughout the next
12 months;
- Collectively commit to prioritizing the issue of counterfeit
medical products through a regional “Call to Action”.

IMACT and OUTCOME
The WHPA Abuja “call to action” on counterfeit medical
products
The “WHPA Abuja Call to Action on Counterfeit Medical
Products” was approved unanimously and states:
We, national member organisations of the International
Council of Nurses (ICN), the International Pharmaceutical
Federation (FIP), the World Confederation for Physical
Therapy (WCPT), the World Dental Federation (FDI) and the
World Medical Association (WMA) are meeting in Abuja, Nigeria,
on the 22–23 November 2010, to address the alarming threat
of falsified and counterfeit medical products in Africa.
In attendance, are patient support and consumer groups
as well.
We note with grave concern that the problem of poor quality
medicines, particularly falsification and counterfeiting of
medical products is on the increase and that about a half of
medical products in some regions of Africa may be counterfeit.
We recognise that significant steps have been taken to fight
medicines counterfeiting by some African governments and
their regulatory bodies, health professional organisations and

31

32

FIP ANNUAL REPORT 2010-2011

international organisations such as the World Health Organization (WHO). However, there remains a need to ensure a zero
tolerance to medicines counterfeiting as curbing this heinous
crime is primary to any significant improvements that may be
made in the Millennium Development Goals (MDGs). Health
professionals are uniquely positioned in this fight and must rise
up to the challenge to increase the awareness of this problem
and implement definitive strategies towards curbing it.

Next steps
WHPA and the health care professionals who participated in
this workshop are keen to ensure that the energy and momentum that has been generated is not lost. To this end all HCPs
who participated in the workshop are encouraged to:

We therefore commit ourselves, as leaders representing nurses,
pharmacists, physical therapists, dentists and physicians, to
accelerate our response to this problem by:
- empowering patients and the consumers with the knowledge needed to avoid falsified and counterfeit medicines.

- Share with your Ministry of Health and the media about the
Abuja Call to Action and WHPA toolkit.

- supporting our national drug regulatory authorities and
relevant government agencies to aid pharmaceutical
guideline enforcement and by assisting in developing
national reporting systems that enable health professionals
to report and to get feedback about adverse events, medicine-related problems, medication errors, misuse or medicine
abuse, defects in product quality or detection of falsified and
counterfeit medical products.

- Disseminate the Abuja Call to Action and workshop materials
to your own members.

- Is there a national committee or association of multi-disci­
plinary professional associations? If yes, is combating
counterfeit medical products on their agenda? Could they
organize a national workshop with HCP and other stake­
holders? If no, could a meeting be organized to talk about
setting such a group in the country?

- working with medicines manufacturers, national quality
control laboratories, hospitals and universities to learn about
quality products and ways of detecting counterfeits as well
as provide continuing education programmes to health
professionals on the detection and reporting of counterfeits.
- establish inter professional collaboration so that health
professionals and patient support groups can begin to tap
from each other’s core competencies in fighting this public
health threat.
We strongly urge governments in our countries to:
- Adopt the WHO definition of falsified and counterfeit medical
products so that access to legitimate, safe, effective and
affordable generic medicines will not be hindered by
inappropriate intellectual property rights enforcement.
- To implement and enforce relevant legislations and regulations that will prevent, control and reduce the incidence of
counterfeit medicines.
- To strengthen the integrity of the medicines supply, procurement and distribution systems.

33

34

FIP ANNUAL REPORT 2010-2011

SHARING KNOWLEDGE.
AROUND THE WORLD.
FIP Officers around the word
As FIP continues to implement its mission, vision and strategic
plan, the Federation is becoming more and more recognised
for its expertise within all manner of pharmaceutical science,
pharmacy practice and the advancement of pharmacy
education on a global level. This expertise is exemplified in
the knowledge and work of FIP Officers and Staff, who are
increasingly asked to lead and speak at meetings all over the
world, spanning, as mentioned, all disciplines under the
umbrella philosophy of “pharmacy”.
The interactive map to follow illustrates the presence of
FIP Officers and Staff at meetings, seminars and workshops
throughout 2010-2011. This is where FIP has shared it’s
­knowledge around the world.

35

36

FIP ANNUAL REPORT 2010-2011

37

38

FIP ANNUAL REPORT 2010-2011

FINANCES.
BALANCE SHEET AT DECEMBER 31ST, 2010 – After appropriation of the result for 2010 (Expressed in EUR)

DECEMBER 31 2010

DECEMBER 31 2011

1

643 574

661 879

Debtors, prepayments and accrued income

2

564 615

276 658

Cash at bank and in hand

3

1 351 051

1 685 018

TOTAL CURRENT ASSETS

1 915 666

1 961 676

TOTAL ASSETS

2 559 240

2 623 555

FIXED ASSETS
CURRENT ASSETS

CAPITAL AND RESERVES
Capital

4

1 101 782

1 282 067

Congress reserve

4

453 780

453 780

Board of Pharmaceutical Practice reserve

5

39 383

12 697

Board of Pharmaceutical Sciences reserve

5

181 692

209 284

Regional Forums Reserve

6

23 035

36 204

Reserve Centennial

6

300 000

300 000

Reserve HIV/AIDS

6

10 000

10 000

2 109 672

Total Capital and Reserves

2 304 033

PROVISIONS

7

30 000

15 000

CURRENT LIABILITIES

8

419 568

304 523

2 559 240

2 623 555

TOTAL CAPITAL AND RESERVES AND LIABILITIES

39

STATEMENT OF INCOME AND EXPENDITURE FOR THE YEAR 2010 – Expressed in EUR

ACTUALS 2010

BUDGET 2010

BUDGET VS ACTUALS

ACTUALS 2009

INCOME
Membership fees

9

808 520

865 000

(56 480)

835 033

FIP World Congress revenues

10

1 655 563

1 650 000

5 563

1 591 423

PSWC Congress revenues

10

143 449

300 000

(156 551)

WHPCR Congress revenues

10

25 000



25 000



Publications

11

2 937

5 000

(2 063)

7 007

Other income BPS

20

1 528



1 528

3 682

23/24

85 560

120 000

(34 440)

103 243







22 408

38 091

5 000

33 091

63 637

2 760 648

2 945 000

(184 352)

2 626 433

Sections income
WHO/Impact income
Other income

12

TOTAL INCOME

EXPENSES
Personnel costs

13

882 064

870 000

12 064

817 101

Office costs

14

234 349

240 000

(5 651)

216 177

Meeting costs

14

147 240

150 000

(2 760)

150 504

Travel expenses (Ext. Representation)

14

29 763

70 000

(40 237)

63 455

65 832

80 000

(14 168)

83 891

Depreciation of fixed assets

1

22 539

25 000

(2 461)

26 584

Website and IT-costs

Special Projects (incl. Reg. Forums & PET)

15

82 120

120 000

37 880

162 282

Direct FIP World congress costs

16

1 109 622

1 005 500

104 122

914 951

Direct PSWC congress costs

16

56 083

50 000

6 083



Direct WHPCR congress costs

16

9 437



9 437



Publications

17

75 757

60 000

15 757

79 730

Subventions

18

8 500

8 500



9 500

Expenses BPP

19

74 659

102 000

(27 341)

120 822

Expenses BPS

20

77 775

50 000

27 775

77 921

Sections costs

23/24

91 102

120 000

(28 898)

119 084

7

15 000

10 000

5 000

15 000

Maintenance Fund
WHO/Impact expenses







328

Other expenses



4 000

4 000



TOTAL EXPENSES

2 981 842

2 965 000

16 842

2 857 330

OPERATING RESULT

(221 194)

(20 000)

(201 194)

(230 897)

26 8334

20 000

6 834

32 087

(194 360)



(194 360)

(198 810)

Financial result

21

NET RESULT BEFORE APPROPRIATION

40

Appropriation of the results, (from)/to:
BPP General Reserves

5/19

26 686

(19 477)

23/24

91 102

120 000

(28 898)

119 084

7

Sections costs

15 000

10 000

5 000

15 000







328

Maintenance Fund
WHO/Impact expenses



TOTAL EXPENSES

4 000

4 000



2 981 842

Other expenses

2 965 000

16 842

2 857 330

FIP ANNUAL REPORT 2010-2011
(221 194)

OPERATING RESULT

Financial result

21

NET RESULT BEFORE APPROPRIATION

(20 000)

(201 194)

(230 897)

26 8334

20 000

6 834

32 087

(194 360)



(194 360)

(198 810)

Appropriation of the results, (from)/to:
BPP General Reserves

5/19

26 686

(19 477)

BPS General Reserves

(25 584)

5/20

(27 592 )

Regional forums reserve

6

(13 169)

(9 845)

Reserve Centennial

6



100 000

Reserve HIV/AIDS

6





Section Capital

4

(5 542)

(15 841)

FIP Capital

4

(174 743)

(228 063)

TOTAL APPROPRIATION

(194 360)



(194 360)

(198 810)

41

COLOPHON.

Federation Internationale Pharmaceutique (FIP)
Postal address
PO Box 84200
2508 AE The Hague
The Netherlands
Street address
Andries Bickerweg 5
2517 JP The Hague
The Netherlands
www.fip.org

WALLPAPERS.
TO BE DOWNLOADED

42

Art Direction/Design
United 135, The Netherlands
Karim Cherif, Lian Aelmans
www.united135.com